Texolite Dry Fill

Manufacturer: United States Gypsum Company Product Category: Pipe Insulation Years Produced: 1959–1961 Asbestos Type: Chrysotile Legal Tier: Litigated (No Active Trust Fund)

Product Description

Texolite Dry Fill was a pipe insulation product manufactured by United States Gypsum Company (USG) during a narrow production window between 1959 and 1961. USG was among the most prominent building materials manufacturers in the United States throughout the twentieth century, and its product lines during the mid-century period frequently incorporated asbestos as a functional component. Texolite Dry Fill was marketed and sold during an era when asbestos-containing insulation materials were widely considered standard practice in industrial and commercial construction.

As its name suggests, Texolite Dry Fill was designed to be applied in a dry fill capacity, meaning it was used to insulate pipes by being packed or poured into place rather than applied as a wet slurry or pre-formed section. This type of application was common in industrial settings where pipes required thermal protection and where loose or granular insulation materials offered flexibility in filling irregular spaces, joints, or cavities around pipe systems. The product was positioned within USG’s broader insulation product line and was available during the late 1950s and very early 1960s before being discontinued.

United States Gypsum Company has been named as a defendant in asbestos personal injury litigation across multiple decades. Although USG itself reorganized under Chapter 11 bankruptcy proceedings in 2001 — in part due to the weight of asbestos-related claims — the company emerged from bankruptcy in 2006 and does not operate through an asbestos bankruptcy trust in the same manner as manufacturers who permanently assigned their liabilities to a Section 524(g) trust. Claims related to specific USG products, including those in the Texolite line, have proceeded through civil litigation rather than through a centralized trust fund claims process.

Asbestos Content

Texolite Dry Fill contained chrysotile asbestos, the fibrous silicate mineral that accounts for the vast majority of asbestos used commercially in the United States during the twentieth century. Chrysotile, sometimes referred to as white asbestos, is characterized by its curly, flexible fiber structure and was favored in insulation manufacturing for its heat-resistant properties and its ability to bind with other materials to create stable, durable products.

In pipe insulation applications of this era, chrysotile fibers served as the primary reinforcing and insulating component. The mineral’s resistance to high temperatures made it effective at protecting pipe systems carrying steam, hot water, or industrial process fluids from heat loss or heat damage. Chrysotile was also relatively inexpensive and abundantly available through established North American mining operations, making it a commercially attractive choice for manufacturers competing in the industrial insulation market.

Although chrysotile has historically been distinguished from amphibole asbestos varieties such as amosite or crocidolite in certain regulatory and scientific contexts, it is classified as a known human carcinogen by the International Agency for Research on Cancer (IARC) and is regulated as a hazardous material under OSHA and EPA standards. No form of asbestos is considered safe at any level of occupational or environmental exposure under current federal regulatory frameworks.

How Workers Were Exposed

Industrial workers who handled, installed, disturbed, or worked in proximity to Texolite Dry Fill during its production years and in the years following installation faced potential exposure to airborne chrysotile asbestos fibers. The dry fill application method central to this product’s use was particularly associated with fiber release. Unlike pre-formed pipe insulation sections, loose dry fill materials must be handled directly during application — poured, packed, and shaped around pipe surfaces — creating conditions in which fibers can become suspended in the ambient air of the work environment.

Asbestos fibers released during installation or subsequent disturbance are microscopic, invisible to the naked eye, and capable of remaining suspended in air for extended periods. Workers in enclosed or poorly ventilated industrial spaces — such as boiler rooms, mechanical rooms, manufacturing plants, and industrial facilities — faced the greatest risk of inhaling concentrated fiber loads. Inhalation of asbestos fibers is the primary pathway by which asbestos-related diseases develop.

In addition to workers who directly applied the product, secondary or bystander exposure was a recognized hazard in industrial environments. Other tradespeople or workers present in the same space during installation or during maintenance activities that disturbed previously installed insulation could inhale fibers without ever directly touching the material. This pattern of exposure is well documented in occupational health literature and has been extensively examined in asbestos personal injury litigation.

The latency period for asbestos-related diseases — including mesothelioma, asbestosis, and asbestos-related lung cancer — typically ranges from ten to fifty years following initial exposure. This means that workers exposed to products like Texolite Dry Fill during its installation years in the early 1960s may have developed diseases in the decades that followed, with diagnoses potentially occurring well into the 1980s, 1990s, or beyond.

Because United States Gypsum Company does not administer an active Section 524(g) asbestos bankruptcy trust for the Texolite Dry Fill product, individuals seeking legal remedies for asbestos-related diseases associated with this product have pursued claims through civil litigation rather than through a trust fund filing process.

Litigation records document that USG and its Texolite product line have been subjects of asbestos personal injury lawsuits filed in various state and federal jurisdictions. Plaintiffs alleged that exposure to asbestos-containing products manufactured and sold by United States Gypsum Company caused or contributed to the development of serious asbestos-related diseases, including malignant mesothelioma, asbestos-related lung cancer, and asbestosis. Plaintiffs further alleged that the company had knowledge of the hazards associated with asbestos use and failed to adequately warn workers of the risks associated with its products.

Individuals who believe they were exposed to Texolite Dry Fill and who have received a diagnosis of an asbestos-related disease should consult with a qualified asbestos litigation attorney to evaluate their legal options. Key documentation relevant to such cases typically includes employment records demonstrating work history at specific industrial sites, medical records confirming the diagnosis of an asbestos-related condition, and any product identification evidence linking the specific material to the workplace in question.

Because statutes of limitations apply to asbestos personal injury claims and vary by state, individuals with potential exposure histories are advised to seek legal consultation promptly following a diagnosis. An attorney experienced in asbestos litigation can identify all potentially liable parties — which may include product manufacturers, distributors, premise owners, or contractors — and evaluate whether additional claims through existing asbestos bankruptcy trusts of other named defendants may also be applicable to the specific exposure history.

This article is provided for informational and reference purposes. It is not legal advice. Persons seeking legal remedies should consult a licensed asbestos litigation attorney.